Glioblastoma multiforme (GBM) is the most lethal form of brain cancer in adults. Despite a recent explosion of information on the genetic causes of this disease, the average survival of GBM patients is only 15 months and the tumors tend to be resistant to all known therapies. The devastating nature of GBM underscores a dire need for novel therapeutic targets and a better understanding of the molecular mechanisms that drive the growth and maintenance of these tumors. Like other aggressive tumors, GBMs display a high degree of cell proliferation made possible by the activation of a select set of metabolic activities required to generate the energy and macromolecules (lipids, nucleic acids, proteins) needed for cell growth and division. These metabolic activities are attractive therapeutic targets because they lie between the diverse molecular drivers of cellular transformation in GBM and the phenotype of rapid tumor growth that ultimately kills the patient. The main objective of this proposal is to define the metabolic regulators of GBM cell growth in vitro and in vivo. The proposal builds on our novel analytical methods developed to measure metabolism of GBM cells in culture and, for the first time, in intact human GBM tumors grown in the mouse. These methods led to the surprising observation that GBM cells have highly active mitochondria that use either of two metabolic pathways to convert nutrients into precursors required for macromolecular synthesis and growth.
Specific Aim 1 proposes loss-of-function experiments with RNA interference to identify key metabolic regulators that allow GBM cells to use the amino acid glutamine as the preferred mitochondrial substrate.
Specific Aim 2 proposes similar experiments to define the key metabolic regulators in an alternative metabolic pathway that does not require glutamine but still allows tumor cells to grow rapidly in culture and in vivo.
Specific Aim 3 proposes to study metabolism in twenty independent human GBM tumors grown exclusively in the mouse brain to understand how tumor mutations influence metabolic activity, and whether particular mutations define sensitivity to the suppression of metabolic activities in vivo. All three Specific Aims feature extensive metabolic analysis of live tumors using nuclear magnetic resonance spectroscopy and mass spectrometry, and will produce a unique view of GBM metabolism with an unprecedented level of detail and biological accuracy. Together, these experiments will pinpoint a new set of metabolic activities that distinguish GBM tumors from normal brain, will define mechanisms that connect malignant transformation to cellular metabolism, and will identify metabolic targets that should lead to novel therapeutic approaches in GBM and potentially other aggressive cancers.

Public Health Relevance

Glioblastoma multiforme (GBM), the most lethal form of brain cancer, is highly resistant to chemotherapy and radiation. GBM tumors can grow rapidly because their metabolism is orchestrated so as to maximize the production of building blocks required for cell proliferation within the tumor. We previously identified many of the metabolic pathways involved in this process, and here we will identify which of these are the critical regulators of tumor cell growth in culture and in mice, thus laying a foundation for novel therapeutic strategies in GBM and other aggressive forms of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Program Officer
Lin, Alison J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Schools of Medicine
United States
Zip Code
Dutchak, Paul A; Estill-Terpack, Sandi J; Plec, Abigail A et al. (2018) Loss of a Negative Regulator of mTORC1 Induces Aerobic Glycolysis and Altered Fiber Composition in Skeletal Muscle. Cell Rep 23:1907-1914
Shi, Xiaolei; Tasdogan, Alpaslan; Huang, Fang et al. (2017) The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv 3:eaao5268
Kim, Jiyeon; Hu, Zeping; Cai, Ling et al. (2017) CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 546:168-172
Vander Heiden, Matthew G; DeBerardinis, Ralph J (2017) Understanding the Intersections between Metabolism and Cancer Biology. Cell 168:657-669
Jiang, Lei; Boufersaoui, Adam; Yang, Chendong et al. (2017) Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein. Metab Eng 43:198-207
Silvers, Molly A; Deja, Stanislaw; Singh, Naveen et al. (2017) The NQO1 bioactivatable drug, ?-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. J Biol Chem 292:18203-18216
Goveia, Jermaine; Pircher, Andreas; Conradi, Lena-Christin et al. (2016) Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol Med 8:1134-1142
Ouyang, Qing; Nakayama, Tojo; Baytas, Ozan et al. (2016) Mutations in mitochondrial enzyme GPT2 cause metabolic dysfunction and neurological disease with developmental and progressive features. Proc Natl Acad Sci U S A 113:E5598-607
DeBerardinis, Ralph J; Chandel, Navdeep S (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200
Padanad, Mahesh S; Konstantinidou, Georgia; Venkateswaran, Niranjan et al. (2016) Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep 16:1614-1628

Showing the most recent 10 out of 65 publications